DESAL-HEART: Hypertonic Saline Added to a Pre-declared Furosemide Dose in Acute Heart Failure
NCT07927127, Phase 4, Not yet recruiting, University of Alberta
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | DESAL-HEART: Hypertonic Saline Added to a Pre-declared Furosemide Dose in Acute Heart Failure | ClinicalTrials.gov |
| NCT number | NCT07927127 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 4 | ClinicalTrials.gov |
| Enrollment | 60 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of Alberta | ClinicalTrials.gov |
| Conditions | Acute Heart Failure (AHF), Acute Decompensated Heart Failure | ClinicalTrials.gov |
| Interventions | Hypertonic Saline (3% Sodium Chloride), Furosemide (Diuretic) | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change From Baseline in NT-proBNP at 24 Hours | Baseline to 24 hours after randomization | Change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) from baseline to 24 hours after randomization. NT-proBNP is a blood biomarker of heart failure. | ClinicalTrials.gov |
| Secondary | Spot Urine Sodium Concentration at 90-150 Minutes | 90-150 minutes after randomization | Spot urine sodium concentration measured 90-150 minutes after randomization to assess the early natriuretic response to intravenous furosemide with or without hypertonic saline. | ClinicalTrials.gov |
| Secondary | Change From Baseline in NT-proBNP at 48 Hours | Baseline to 48 hours after randomization | Change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) from baseline to 48 hours after randomization to assess the persistence of the treatment effect on this heart failure biomarker | ClinicalTrials.gov |
| Secondary | Spot Urine Sodium Concentration at 6 Hours | First urine void more than 6 hours after randomization | Spot urine sodium concentration measured from the first urine sample collected more than 6 hours after randomization to assess the sustained natriuretic response to treatment. The actual sample collection time will be recorded. | ClinicalTrials.gov |
| Secondary | Change From Baseline in Hemoglobin at 24 Hours | Baseline and 24 hours after randomization | Change in blood hemoglobin concentration from baseline to 24 hours after randomization, measured using routine complete blood count testing. | ClinicalTrials.gov |
| Secondary | Change From Baseline in Hematocrit at 24 Hours | Baseline and 24 hours after randomization | Change in hematocrit from baseline to 24 hours after randomization, measured using routine complete blood count testing | ClinicalTrials.gov |
| Secondary | Change From Baseline in Body Weight at 24 Hours | Baseline and 24 hours after randomization | Change in body weight from baseline to 24 hours after randomization to assess fluid removal and decongestion. | ClinicalTrials.gov |
| Secondary | Total Urine Output Through 24 Hours | Randomization through 24 hours | Total recorded urine output during the first 24 hours after randomization to assess the diuretic response to treatment. | ClinicalTrials.gov |
| Secondary | Net Fluid Balance Through 24 Hours | Randomization through 24 hours | Net fluid balance, calculated as total recorded fluid intake minus total recorded fluid output during the first 24 hours after randomization. | ClinicalTrials.gov |
| Secondary | Total Furosemide-Equivalent Dose Through 24 Hours | Randomization through 24 hours | Total furosemide-equivalent diuretic dose administered during the first 24 hours after randomization, including the pre-declared study dose and subsequent diuretic treatments. | ClinicalTrials.gov |
| Secondary | Other Decongestive Therapies Through 24 Hours | Randomization through 24 hours | Use of additional decongestive therapies during the first 24 hours after randomization, including treatments administered at the discretion of the treating physician. | ClinicalTrials.gov |
| Secondary | Change From Baseline in Serum Sodium | Baseline and 24 hours | Change in serum sodium concentration from baseline to 24 hours after randomization. | ClinicalTrials.gov |
| Secondary | Change From Baseline in Serum Chloride | Baseline and 24 hours | Change in serum chloride concentration from baseline to 24 hours after randomization. | ClinicalTrials.gov |
| Secondary | Change From Baseline in Serum Potassium | Baseline and 24 hours | Change in serum potassium concentration from baseline to 24 hours after randomization. | ClinicalTrials.gov |
| Secondary | Change From Baseline in Serum Bicarbonate | Baseline and 24 hours | Change in serum bicarbonate concentration from baseline to 24 hours after randomization. | ClinicalTrials.gov |
| Secondary | Change From Baseline in Serum Creatinine | Baseline and 24 hours | Change in serum creatinine concentration from baseline to 24 hours after randomization to assess kidney function. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)